{
  "chapter": "And Parenteral Anticoagulants",
  "questions": [
    {
      "q_no": 1,
      "question": "A 72-year-old woman with a history of atrial fibrillation and a recent deep vein thrombosis (DVT) is admitted to the hospital. The physician decides to initiate anticoagulation therapy with warfarin to prevent further thromboembolic complications. Which of the following best describes the mechanism of action of warfarin?",
      "options": {
        "A": "Inhibits the synthesis of fibrin",
        "B": "Inhibits platelet aggregation",
        "C": "Inhibits the synthesis of vitamin K-dependent clotting factors",
        "D": "Directly binds to and inactivates thrombin"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Inhibits the synthesis of vitamin K-dependent clotting factors Explanation: By inhibiting the synthesis of vitamin K-dependent clotting factors, warfarin reduces the risk of clot formation and helps prevent adverse events like stroke or recurrent DVT. Mechanism of action: Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 667",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/And_Parenteral_Anticoagulants_Q1_exp.png",
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 2,
      "question": "A 58-year-old woman with a history of mitral valve replacement (on warfarin) and trigeminal neuralgia (on carbamazepine) has been prescribed clarithromycin for a chest infection. Her regular medications include amlodipine and atorvastatin. Her INR is 1.3 (target > 3 for mechanical heart valve). Which drug most likely interacted with warfarin to give this INR?",
      "options": {
        "A": "Amlodipine",
        "B": "Atorvastatin",
        "C": "Clarithromycin",
        "D": "Carbamazepine"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Carbamazepine Explanation: Carbamazepine is a strong enzyme inducer , particularly of CYP2C9 and CYP3A4 , which are responsible for metabolizing warfarin. Enzyme induction leads to increased metabolism of warfarin , resulting in reduced plasma levels and a lower INR (as seen in this case: INR 1.3). This is dangerous in patients with mechanical heart valves who require INR > 3 to prevent thromboembolic complications. Mechanism table : Drug Effect on Warfarin Mechanism Carbamazepine ↓ INR ( ↓ warfarin effect) CYP inducer → ↑ warfarin metabolism Clarithromycin ↑ INR ( ↑ warfarin effect) CYP inhibitor → ↓ warfarin metabolism Amlodipine No significant effect No major CYP interaction Atorvastatin Mild unpredictable changes Competes with warfarin at CYP enzymes Pharmacokinetics of Warfarin: Parameter Details Absorption Oral Kinetics Zero-order kinetics at high doses Excretion Excreted in bile , safe in renal failure Protein Binding 99% bound to albumin Dialysis Removal Not dialyzable due to high protein binding Important Drug Interactions with Warfarin: Enzyme Inhibitors ( ↑ INR) – Mnemonic: SICKFACES.COM Drug Sodium Valproate Isoniazid Cimetidine Ketoconazole Fluconazole Alcohol (binge) Chloramphenicol Erythromycin Sulfonamides Ciprofloxacin Omeprazole Metronidazole Enzyme Inducers ( ↓ INR) – Mnemonic: CRAP GPS Drug Carbamazepine Rifampin Alcohol (chronic) Phenytoin Griseofulvin Phenobarbital Sulphonylureas Amlodipine (Option A): Incorrect. No major effect on INR or warfarin metabolism. Atorvastatin (Option B): Incorrect. May have minor interactions but not a strong inducer/inhibitor. Clarithromycin (Option C): Incorrect. Would increase INR, not decrease it. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 670",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 3,
      "question": "An 82-year-old man presents to the emergency department with a sudden onset of severe headache and altered mental status. His CT Scan reveals an intracranial haemorrhage. He has a history of atrial fibrillation and has been taking warfarin. His INR is 5.8. Which of the following is the most appropriate treatment?",
      "options": {
        "A": "Fresh Frozen Plasma",
        "B": "Tranexamic acid",
        "C": "Vitamin K",
        "D": "Prothrombin complex concentrate"
      },
      "correct_answer": "D",
      "explanation": "Correct answer: D) Carbamazepine Explanation: An intracranial haemorrhage in a patient on warfarin is considered a major bleed, necessitating the rapid reversal of anticoagulation. Prothrombin complex concentrate (PCC) is a concentrated source of clotting factors. PCC acts faster than fresh frozen plasma and vitamin K to restore the clotting factors and reduce the INR. Warfarin and high INR management: Major bleeding Stop warfarin. Administer prothrombin complex concentrate. Administer intravenous vitamin K1. If prothrombin complex concentrate is not available, give fresh frozen plasma. INR > 8 with minor or no bleeding Stop warfarin. Administer intravenous or oral vitamin K1. Restart warfarin when INR is < 5. INR 5 - 8 with minor bleeding INR 5 - 8 with no bleeding Stop warfarin. Restart warfarin when INR is < 5. INR above target range but < 5 Reduce or omit one or two doses of warfarin Measure INR in 2-3 days Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 669",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 4,
      "question": "A 68-year-old patient is being evaluated for the initiation of warfarin therapy for various indications. Which of the following indications for warfarin therapy requires the highest target INR range?",
      "options": {
        "A": "Atrial fibrillation (non-valvular)",
        "B": "Deep vein thrombosis (DVT) prophylaxis",
        "C": "Mechanical heart valve replacement",
        "D": "Myocardial infarction (MI) prevention"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Mechanical heart valve replacement Explanation: For patients with mechanical heart valve replacements, warfarin therapy requires a higher target INR range of 3.0 to 3.5. This higher intensity of anticoagulation is necessary to prevent thromboembolic complications associated with mechanical valves. Use Target INR Range Atrial Fibrillation 2.0 - 2.5 Venous Thromboembolism (VTE) Prophylaxis Bioprosthetic Heart Valves (first 3 months) Post-Myocardial Infarction Treatment of DCT, PE, TIA 2.5 - 3.0 Mechanical Prosthetic Heart Valves 3.0 - 3.5 Recurrent Thromboembolism Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 669",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 5,
      "question": "A 72-year-old man has been taking Warfarin 7mg daily for the treatment of left arm DVT for the past 2 years. He also takes furosemide 40mg for HTN. He is usually compliant with his medications. What is the most important adverse effect the patient should be careful with?",
      "options": {
        "A": "Peripheral Neuropathy",
        "B": "Phototoxicity",
        "C": "Headache",
        "D": "Constipation"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Headache Explanation: The most important adverse effect of warfarin is headache, which may result from intracranial haemorrhage. Patients should be counselled to report any unusual or persistent headaches while taking Warfarin. HTN is also a risk factor for intracranial haemorrhage. Adverse Effects : Bleeding: Ecchymosis (bruising), Epistaxis, Hematuria, Gastrointestinal bleeding, Intracranial or other internal haemorrhages, which can be fatal. Frequent gastrointestinal disturbances Oral ulceration Dermatitis Urticaria (hives) Alopecia (hair loss) Contraindications for Warfarin: Bleeding disorders. Severe hypertension (risk of cerebral haemorrhage), threatened abortion, piles, gastrointestinal ulcers (risk of aggravated bleeding). Subacute bacterial endocarditis (risk of embolism), large malignancies (risk of bleeding in the central necrosed area of the tumour), tuberculosis (risk of hemoptysis). Ocular and neurosurgery, lumbar puncture. Chronic alcoholics, cirrhosis, renal failure. Aspirin and other antiplatelet drugs should be used very cautiously during warfarin therapy. Early Pregnancy: Increases birth defects, especially skeletal abnormalities; can produce fetal warfarin syndrome (stippled epiphysis, eye socket, hand bones, and growth retardation). Later in Pregnancy: Can cause CNS defects, fetal haemorrhage, fetal death, and accentuates neonatal hypoprothrombinemia. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 665,670",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 6,
      "question": "Which oral anticoagulant is known for inhibiting activated Factor Xa and is used for prophylaxis and treatment of deep vein thrombosis (DVT)?",
      "options": {
        "A": "Warfarin",
        "B": "Dabigatran",
        "C": "Apixaban",
        "D": "Ethylbiscoumacetate"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Apixaban Explanation: Apixaban, an oral anticoagulant, directly inhibits activated Factor Xa, thereby reducing clot formation by preventing the conversion of prothrombin to thrombin. NOVEL ORAL ANTICOAGULANTS: Category Direct Factor Xa Inhibitors Direct Thrombin Inhibitors Mechanism of action Inhibit Factor Xa directly Inhibit thrombin (Factor IIa) directly Drugs Apixaban, Rivaroxaban, Edoxaban, Betrixaban Dabigatran, Ximelagatran Uses Prophylaxis of venous thromboembolism following knee or hip replacement surgery. Prophylaxis of stroke in patients with atrial fibrillation. Treatment of deep vein thrombosis and pulmonary embolism. Advantages of novel anticoagulants over warfarin Rapid onset and offset of action. No need for routine laboratory monitoring. Lower risk of bleeding. Fewer drug interactions. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 671",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 7,
      "question": "Which form of Vitamin K is used as an antidote for coumarin anticoagulant overdose, such as warfarin?",
      "options": {
        "A": "Vitamin K1",
        "B": "Vitamin K2",
        "C": "Vitamin K3",
        "D": "Vitamin K4"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) Vitamin K1 Explanation: Vitamin K1 (phytonadione) is an antidote for coumarin anticoagulant overdose, such as warfarin, by promoting the synthesis of clotting factors in the liver. VITAMIN K: Forms Use Adverse Effects Vitamin K1 (Phytonadione) Antidote for coumarin anticoagulant overdose (e.g., warfarin). Prophylaxis and treatment of Vitamin K deficiency bleeding. Newborns to prevent hemorrhagic disease of the newborn. Severe anaphylactoid reactions on IV injection. Vitamin K2 (Menaquinone) (Option B) Bone metabolism and Calcium regulation in bones and arteries. Used in osteoporosis. Generally considered safe. Very few reported adverse effects. Vitamin K3 (Menadione) (Option C) Not commonly used for anticoagulant reversal. Hemolysis (especially in G6PD deficiency). Risk of kernicterus in newborns. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 661",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 8,
      "question": "Which drugs exert their anticoagulant effect primarily by binding to antithrombin III (AT-III) to inhibit factor Xa selectively?",
      "options": {
        "A": "Lepirudin",
        "B": "Dabigatran",
        "C": "Fondaparinux",
        "D": "Heparin"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Fondaparinux Explanation: Fondaparinux is a synthetic pentasaccharide that exerts its anticoagulant effect by binding to antithrombin III (AT-III) and selectively inhibiting factor Xa through enhanced AT-III activity. It does not directly inhibit thrombin (factor IIa), making it a specific factor Xa inhibitor. Type Mechanism of Action Drugs Direct Thrombin Inhibitors Inhibit thrombin (factor IIa) directly without cofactors. Hirudin derivatives: Hirudin, Lepirudin. Non-hirudin (Synthetic): Argatroban, Bivalirudin. Indirect Thrombin Inhibitors Enhance antithrombin III activity to inhibit thrombin indirectly. Unfractionated Heparin: Heparin Long chain of molecule bind to both factor 2 and 10 Low Molecular Weight Heparin (LMWH): Enoxaparin, Dalteparin, Tinzaparin Long chain of molecule binds to factor 10 > 2 Ultra Low Molecular Weight Heparin (ULMWH): Fondaparinux, Idraparinux, Danaparoid (not commonly used) Long chain of molecule bind selectively to factor 2 Synthetic Direct Factor Xa Inhibitors Bind directly to factor Xa to inhibit its activity. Fondaparinux, Idraparinux Lepirudin (Option A): Incorrect- acts as a direct thrombin inhibitor , not through AT-III. Dabigatran (Option B): Incorrect- directly inhibits thrombin , and does not bind to AT-III. Heparin (Option D): Incorrect- although it binds to AT-III, it inhibits both factor Xa and thrombin , not selectively Xa . Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 666",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 9,
      "question": "Which of the following statements is not true regarding the features of various types of heparin?",
      "options": {
        "A": "ULMW heparin has the shortest half-life.",
        "B": "LMW heparin is primarily excreted through urine.",
        "C": "HMW heparin requires monitoring of aPTT.",
        "D": "Fondaparinux is a synthetic pentasaccharide heparin"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) ULMW heparin has the shortest half-life . Explanation: ULMW (Ultra-low molecular weight) heparin has the longest half-life among the three types (HMW, LMW, and ULMW). Type of Heparin Mechanism of Action Features High Molecular Weight (HMW) Heparin (unfractionated) Binds to antithrombin III, inhibits thrombin and factor Xa. Derived from porcine intestine or bovine lung. Requires monitoring of aPTT Shorter half-life. Safe in renal failure Low Molecular Weight (LMW) Enoxaparin, Dalteparin Preferentially inhibits factor Xa. Derived from LMW fragments of unfractionated heparin. Primarily renal excretion Monitoring of anti-factor Xa levels. Ultra Low Molecular Weight (ULMW) Fondaparinux Selectively inhibits factor Xa. Synthetic pentasaccharide Longer half-life. No routine monitoring is needed for coagulation parameters. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 664",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 10,
      "question": "A 65-year-old man who was admitted to the ICU due to septicemia started showing features of disseminated intravascular coagulation. He was then started on a parenteral anticoagulant injection. Which of the following anticoagulants was most probably used in this patient?",
      "options": {
        "A": "Fondaparinux",
        "B": "Enoxaparin",
        "C": "Unfractionated heparin",
        "D": "All of the above"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Unfractionated heparin Explanation: Unfractionated heparin is the drug of choice for Disseminated intravascular coagulation (DIC), as it has Rapid onset of action is crucial during the management of DIC. A short half-life helps in quick cessation of action if needed. Toxicity can be easily reversed with protamine sulfate. The dose can be titrated by monitoring apTT. Uses Contraindication HMWH Unfractionated heparin (Option C) Disseminated intravascular coagulation Hemodialysis Atrial fibrillation Maintain patency of cannulae and shunts. Any major bleed Thrombocytopenia Heparin-induced thrombocytopenia Cerebrovascular accident Aneurysm Recent CNS surgery or ophthalmic surgery Severe renal impairment (except for unfractionated heparin) GIT ulcer Hemophilia Severe uncontrolled hypertension Bacterial endocarditis Hypersensitivity to heparin Large malignancies Liver cirrhosis Tuberculosis LMWH Dalteparin Enoxaparin (Option B) Tinzaparin Prophylaxis of Deep vein thrombosis & Pulmonary embolism Treatment of Acute coronary syndrome & Antiphospholipid syndrome. ULMWH Fondaparinux (Option A) Idraparinux Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 663-666",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 11,
      "question": "A 48-year-old man who was recently diagnosed with unstable angina was started on heparin. After 2 days, he developed ‘Heparin-induced thrombocytopenia’. Which of the following types of heparin is not associated with HIT?",
      "options": {
        "A": "Unfractionated heparin",
        "B": "Enoxaparin",
        "C": "Dalteparin",
        "D": "Fondaparinux"
      },
      "correct_answer": "D",
      "explanation": "Correct answer: D ) Fondaparinux Explanation: Fondaparinux is a synthetic ultra-low molecular weight heparin that is not associated with heparin-induced thrombocytopenia. Adverse effects of heparin: Hemorrhage due to heparin toxicity 1st sign is hematuria, which can affect the GIT, CVS and joints. Antidote - Protamine sulfate (most effective against UFH and least effective against ULMWH). Heparin-induced thrombocytopenia Serotonin assay shows elevated levels of serotonin (released from platelet) Management - discontinue heparin + start on direct thrombin inhibitor (argatroban, lepirudin) All types of heparin except for Fondaparinux cause HIT Other adverse effects of heparin: Hyperkalemia (due to aldosterone synthesis inhibition) Osteoporosis Transient and reversible alopecia Hypersensitivity reaction (rigor, chills, fever and anaphylaxis) Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 665 https://pubmed.ncbi.nlm.nih.g ov/7778574/#:~:text=Results%3A%20Heparin%20and%20its%20congeners,other%20corticosteroids%20are%20n ot%20affected .",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/And_Parenteral_Anticoagulants_Q11_exp.jpg",
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 12,
      "question": "Which anticoagulant is preferred for treating patients with heparin-induced thrombocytopenia (HIT) due to its specific indication, effectiveness in avoiding cross-reactivity with heparin antibodies, and safety profile?",
      "options": {
        "A": "Warfarin",
        "B": "Fondaparinux",
        "C": "Argatroban",
        "D": "Enoxaparin"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Argatroban Explanation: Argatroban is a direct thrombin inhibitor that binds directly to the active site of thrombin, inhibiting its activity. Unlike heparin, which enhances the activity of antithrombin III (AT-III), argatroban does not require AT-III for its anticoagulant effect. This makes it effective in patients with heparin-induced thrombocytopenia (HIT), where antibodies to heparin-platelet factor 4 complexes cause immune-mediated thrombosis. Aspect Argatroban Mechanism of Action (MOA) It is a direct thrombin inhibitor that binds reversibly to the catalytic site of thrombin, inhibiting its activity. It prevents thrombin-mediated conversion of fibrinogen to fibrin and inhibits platelet activation and aggregation. Adverse Effects Bleeding (ranging from minor to severe haemorrhage). Hypersensitivity reactions. Elevated liver enzymes. Local irritation at the injection site. Uses Prophylaxis and treatment of thrombosis in patients at risk of HIT. Contraindications Active major bleeding Hypersensitivity to Argatroban. Severe hepatic impairment. Concomitant use with strong CYP3A4 inhibitors. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 667",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 13,
      "question": "A 28-year-old pregnant female who is in her first trimester was diagnosed with antiphospholipid syndrome. As a prophylaxis for thrombosis and risk of miscarriage, anticoagulant therapy was started. Which of the following anticoagulant agents is unsafe to use during the first trimester of pregnancy?",
      "options": {
        "A": "Fondaparinux",
        "B": "Warfarin",
        "C": "Dalteparin",
        "D": "Unfractionated heparin"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Warfarin Explanation: Warfarin is contraindicated in the first trimester of pregnancy as it is teratogenic, leading to Congenital warfarin syndrome. If used early in pregnancy Hypoplasia of the nose (saddle nose), eye sockets. Hypoplasia of limbs. Growth retardation. And if used later in pregnancy, it can lead to CNS defects. Fetal haemorrhage. Neonatal hypoprothrombinemia. Heparin is safe to use during pregnancy since it does not cross the placenta, and it is employed in conditions such as antiphospholipid syndrome, deep vein thrombosis, and pulmonary embolism. Novel oral anticoagulants (NOAC) such as Dabigatran and Apixaban are also not preferred during pregnancy or lactation. Gestational period Anticoagulants preferred 0-12 weeks LMW/ULMW heparin 12-36 weeks LMW/ULMW heparin As organogenesis is completed, Warfarin may be used only in cases of patients with mechanical prosthetic valves 36 weeks till delivery LMW/ULMW heparin During delivery No anticoagulant is used due to the risk of postpartum hemorrhage During lactation Warfarin is preferred over heparin Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Page 670 https://www.ncbi.nlm.nih.gov/books/NBK430980/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950440/#:~:text =The%20Royal%20College%20of%20Obstetricians,women%20who%20are%20breast%20feeding'.&text=Similarl y%2C%20ACCP%20guidelines%20(2012),in%20pregnancy%20or%20breast%20feeding . https://www.uptodate.co m/contents/management-of-risks-of-prosthetic-valves-during-pregnancy?sectionName=Prosthetic%20valve%20thro mbosis&search=anticoagulants%20in%20pregnancy&topicRef=8126&anchor=H2723388714&source=see_link# H2723388714 https://www.uptodate.com/contents/use-of-anticoagulants-during-pregnancy-and-postpartum?search =anticoagulants%20in%20pregnancy&source=search_result&selectedTitle=1%7E150&usage_type=default&displ",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/And_Parenteral_Anticoagulants_Q13_exp.jpg",
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 14,
      "question": "A 78-year-old male patient presents to the emergency department with features of acute deep vein thrombosis. The patient has a history of atrial fibrillation and chronic kidney disease. He is currently on anticoagulant therapy. Which set of anticoagulants is safe to use in this patient?",
      "options": {
        "A": "Warfarin and Fondaparinux",
        "B": "Warfarin and unfractionated heparin",
        "C": "Unfractionated heparin and Dabigatran",
        "D": "Rivaroxaban and Fondaparinux"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Warfarin and unfractionated heparin Explanation: Warfarin and unfractionated heparin are safe for patients with chronic kidney disease. Drug Excretion Safety in renal disease Warfarin (Vitamin K antagonist) Hepatic excretion Safe Unfractionated heparin (High molecular weight heparin) Reticuloendothelial cells and hepatic excretion Safe Fondaparinux (Ultra-low molecular weight heparin) Renal excretion Unsafe Dabigatran (Direct thrombin inhibitor) Renal excretion Unsafe Rivaroxaban (Direct factor Xa inhibitor) Renal and hepatic excretion Unsafe Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Pages 664-671",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    },
    {
      "q_no": 15,
      "question": "Match the following anticoagulants with their antidotes. Anticoagulants Antidote 1. Warfarin A. Protamine Sulfate 2. Heparin B. Andexanet Alfa 3. Dabigatran C. Vitamin K 4. Apixaban D. Idarucizumab",
      "options": {
        "A": "1-B, 2-C, 3-A, 4-D",
        "B": "1-C, 2-A, 3-D, 4-B",
        "C": "1-C, 2-D, 3-B, 4-A",
        "D": "1-B, 2-A, 3-C, 4-D"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) 1-C, 2-A, 3-D, 4-B Explanation: Anticoagulant Antidote Mechanism Warfarin Vitamin K Vitamin K helps reverse the warfarin-induced inhibition of Vitamin K epoxide reductase, resulting in ↑ carboxylation and activation of clotting factors II, VII, IX, and X. Heparin Protamine Sulfate It neutralises and prevents the binding of heparin and antithrombin III. Dabigatran Idarucizumab It is a monoclonal antibody that binds to dabigatran and neutralises its anticoagulant activity. Apixaban Andexanet Alfa It acts as a decoy receptor for apixaban, binds to apixaban, and reverses its anticoagulant effects. Reference: K D Tripathi, Essentials of Medical Pharmacology, 8th Edition, Pages 661, 666, 672 https://www.ncbi.nlm.nih.gov/books/NBK519499/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "And Parenteral Anticoagulants"
    }
  ]
}
